Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $25.1875.

ROIV has been the subject of a number of recent research reports. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings restated a “hold (c-)” rating on shares of Roivant Sciences in a research report on Thursday, January 22nd. HC Wainwright upped their target price on Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a report on Friday, December 12th. The Goldman Sachs Group increased their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Citigroup raised their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th.

Roivant Sciences Stock Up 0.5%

ROIV opened at $22.02 on Friday. The stock has a market capitalization of $15.31 billion, a price-to-earnings ratio of -39.32 and a beta of 1.22. Roivant Sciences has a twelve month low of $8.73 and a twelve month high of $23.91. The company has a 50-day simple moving average of $21.87 and a 200 day simple moving average of $17.32.

Insider Buying and Selling at Roivant Sciences

In other news, CFO Richard Pulik sold 406,731 shares of the company’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the transaction, the chief financial officer owned 239,413 shares of the company’s stock, valued at $5,370,033.59. This represents a 62.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel Allen Gold sold 777,332 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $23.07, for a total transaction of $17,933,049.24. Following the completion of the transaction, the director directly owned 16,353,113 shares of the company’s stock, valued at approximately $377,266,316.91. This trade represents a 4.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,332,392 shares of company stock worth $266,393,645 in the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Penn Davis Mcfarland Inc. increased its holdings in shares of Roivant Sciences by 10.1% in the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock valued at $28,173,000 after acquiring an additional 170,456 shares during the period. Valeo Financial Advisors LLC purchased a new position in Roivant Sciences during the 2nd quarter worth $1,145,000. IFG Advisory LLC acquired a new position in Roivant Sciences in the second quarter valued at $255,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Roivant Sciences in the second quarter valued at about $3,064,000. Finally, Franklin Resources Inc. acquired a new stake in shares of Roivant Sciences during the second quarter worth about $997,000. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.